A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
Anna Sureda,Peter Bader,Simone Cesaro,Peter Dreger,R. F. Duarte,Carlo Dufour,Jhf Falkenburg,D Farge-Bancel,Andrew R. Gennery,Kröger N,Francesco Lanza,Judith C. W. Marsh,Arnon Nagler,C Peters,Andrea Velardi,M. Mohty,Alejandro Madrigal +16 more
TL;DR: This is the sixth special report that the European Society for Blood and Marrow Transplantation regularly publishes on the current practice and indications for haematopoietic SCT for haemsatological diseases, solid tumours and immune disorders in Europe.
Journal ArticleDOI
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia.
Norbert Schmitz,Meral Beksac,Dirk Hasenclever,Andrea Bacigalupo,Tapani Ruutu,Arnon Nagler,Eliane Gluckman,Nigel H. Russell,Jane F. Apperley,Norbert Claude Gorin,Jeff Szer,Kenneth F. Bradstock,Agnès Buzyn,Peter U. Clark,Keith M. Borkett,Alois Gratwohl +15 more
TL;DR: Peripheral blood is an equivalent source of hematopoietic stem cells compared with bone marrow if administered to patients with standard-risk leukemias and long-term observation of patients with different diseases and stages of disease is necessary to define the role of both sources of stem cells.
Journal ArticleDOI
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
Alessandra Larocca,Federica Cavallo,Sara Bringhen,Francesco Di Raimondo,Anna Falanga,Andrea Evangelista,Maide Cavalli,Anfisa Stanevsky,Paolo Corradini,Sara Pezzatti,Francesca Patriarca,Michele Cavo,Jacopo Peccatori,Lucio Catalano,Angelo Michele Carella,Anna Maria Cafro,Agostina Siniscalchi,Claudia Crippa,Maria Teresa Petrucci,Dina Ben Yehuda,Eloise Beggiato,Tommaso Caravita di Toritto,Mario Boccadoro,Arnon Nagler,Antonio Palumbo +24 more
TL;DR: In previously untreated patients with MM receiving lenalidomide with a low thromboembolic risk, ASA could be an effective and less-expensive alternative to LMWH thromboprophylaxis.
Journal Article
Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Shimon Slavin,Elizabeth Naparstek,Arnon Nagler,Aliza Ackerstein,Joseph Kapelushnik,Reuven Or +5 more
TL;DR: The cumulative experience shows that allo-CT can successfully reverse chemoradiotherapy-resistant relapse of acute leukemia and even more effectively of chronic leukemia independently of alpha-interferon therapy.
Journal ArticleDOI
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid,Myriam Labopin,Arnon Nagler,Dietger Niederwieser,Luca Castagna,Reza Tabrizi,Michael Stadler,Jürgen Kuball,Jan J. Cornelissen,Jiri Vorlicek,Gérard Socié,Michele Falda,Lars Vindeløv,Per Ljungman,Graham Jackson,Nicolaus Kröger,Andreas Rank,Emmanuelle Polge,Vanderson Rocha,Mohamad Mohty +19 more
TL;DR: Long-term survival was achieved almost exclusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidation, suggesting that remission duration after transplantation was the only prognostic factor for response.